We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biophytis | EU:ALBPS | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.74 | 0.73 | 0.76 | 0.00 | 01:00:00 |
Stanislas Veillet, Ph.D., Chief Executive Officer of Biophytis said, “We are pleased to have been selected for three oral presentations and a poster at ICFSR 2019. We look forward to sharing the potential of Sarconeos (BIO101) for the treatment of sarcopenia and other muscular dystrophies with leading international clinicians and scientists from industry and academia. We believe Sarconeos (BIO101) is one of the most advanced drug candidates in clinical development for the treatment of sarcopenia, a severe geriatric muscle wasting condition with no currently approved medication.”
Details of the presentations are as follows:
Title: | Sarconeos (API BIO101) targets Mas receptor within the protective arm of the renin angiotensin system and proves efficacy in various models of muscle wasting. |
Presenter: | Pierre Dilda, Ph.D. |
Date/Time: | Wednesday, Feb. 20, 2019 / 5:30 pm EST |
Additional Info: | Oral Communication 10 |
Title: | Insect Steroid Hormones as Human Medicine: Application to Sarcopenia and Muscle Dystrophies. |
Presenter: | Stanislas Veillet, Ph.D. |
Date/Time: | Thursday, Feb. 21, 2019 / 12:25 pm EST |
Additional Info: | Oral Presentation at the Lunch Industry Symposium hosted by Biophytis |
Title: | Designing a clinical program for BIO101, a Mas receptor activator to target age-related sarcopenia. |
Presenter: | Waly Dioh, Ph.D. |
Date/Time: | Thursday, Feb. 21 2019 / 12:25 pm EST |
Additional Info: | Oral Presentation at the Lunch Industry Symposium hosted by Biophytis |
Title: | Evaluation of safety and efficacy of BIO101, a new investigational drug for sarcopenia: a double-blind, placebo controlled, randomized clinical trial. |
Presenter: | Waly Dioh, Ph.D. |
Date/Time: | Thursday, Feb. 21, 2019 |
Additional Info: | Poster: Clinical Trials and Therapeutics P78 |
About BiophytisBiophytis is a clinical-stage biotechnology company focused on the development of novel therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Our therapeutic approach targets key biological resilience pathways that can protect against and counteract the effects of the multiple biological stresses that lead to age-related diseases. Our lead drug candidate, Sarconeos (BIO101), is for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy. Our second drug candidate, Macuneos (BIO201), is for the treatment of retinopathies, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis is based in Paris, France and in Cambridge, Massachusetts. For more information, please visit www.biophytis.com.
BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS; ISIN: FR0012816825).
Follow us on Twitter @biophytis
BIOPHYTIS is eligible for the SMEs scheme
DisclaimerThis press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or at www.biophytis.com.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Biophytis in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.
Biophytis Daniel SCHNEIDERMAN Chief Financial Officerdan.schneiderman@biophytis.comTel: +1 (646) 479-8060
U.S. Media ContactLifeSci Public RelationsCherilyn CECCHINI, M.D.ccecchini@lifescipublicrelations.comTel: +1 (646) 876-5196
Europe Media ContactCitigate Dewe RogersonLaurence BAULT / Antoine DENRYlaurence.bault@citigatedewerogerson.comantoine.denry@citigatedewerogerson.comTel: +33 (0)1 53 32 84 78Mob: +33(0)6 64 12 53 61
1 Year Biophytis Chart |
1 Month Biophytis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions